Keywords
Ovarian cancer
Chemotherapy resistance
Reversal mechanisms
Combination therapy
Submitted : 2026-05-19
Accepted : 2026-06-03
Published : 2026-06-18
Abstract
The development of chemotherapy resistance is a critical factor leading to treatment failure and high mortality in ovarian cancer. Among current research directions, Chinese medicine monomers (CMMs) have shown great potential in reversing chemotherapy resistance due to their multi‑targeting properties and low toxicity. This review summarizes the research progress of various Chinese medicine monomers in reversing chemotherapy resistance in ovarian cancer, including polyphenols (such as quercetin, curcumin, epigallocatechin‑3‑gallate, resveratrol, kaempferol, myricetin, and ellagic acid), alkaloids (such as berberine, piperine, sanguinarine, and capsaicin), terpenoids (such as toosendanin and triptolide), and phenylpropanoids (such as myristicin and apiole). These monomers primarily exert their effects by regulating key signaling pathways (including PI3K/AKT/mTOR, p53, and NF-κB) and by interfering with critical processes such as drug efflux, DNA damage repair, apoptosis, and autophagy, thereby enhancing the sensitivity of ovarian cancer cells to chemotherapeutic agents like cisplatin. Furthermore, this review discusses the advantages of combination strategies involving Chinese medicine monomers, as well as the current challenges.
References
Bray F, Laversanne M, Sung H, et al., 2024, Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 74(3): 229–263.
Gonzalez-Martin A, Harter P, Leary A, et al., 2023, Newly Diagnosed and Relapsed Epithelial Ovarian Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Ann Oncol, 34(10): 833–848.
Havasi A, Cainap SS, Havasi AT, et al., 2023, Ovarian Cancer-Insights into Platinum Resistance and Overcoming It. Medicina (Kaunas), 59(3): 544.
Nag S, Aggarwal S, Rauthan A, et al., 2022, Maintenance Therapy for Newly Diagnosed Epithelial Ovarian Cancer-A Review. J Ovarian Res, 15(1): 88.
Yang L, Zhao H, Yin X, et al., 2020, Exploring Cisplatin Resistance in Ovarian Cancer Through Integrated Bioinformatics Approach and Overcoming Chemoresistance with Sanguinarine. Am J Transl Res, 12(3): 923–939.
Miao K, Liu W, Xu J, et al., 2023, Harnessing the Power of Traditional Chinese Medicine Monomers and Compound Prescriptions to Boost Cancer Immunotherapy. Front Immunol, 14: 1277243.
Wang Y, Xie L, Liu F, et al., 2024, Research Progress on Traditional Chinese Medicine-Induced Apoptosis Signaling Pathways in Ovarian Cancer Cells. J Ethnopharmacol, 319(Pt 2): 117299.
Zhang X, Wei X, Shi L, et al., 2025, The Latest Research Progress: Active Components of Traditional Chinese Medicine as Promising Candidates for Ovarian Cancer Therapy. J Ethnopharmacol, 337(Pt 1): 118811.
Miao L, Liu Y, Ali NM, et al., 2023, Bufalin Serves as a Pharmaceutic That Mitigates Drug Resistance. Drug Metab Rev, 55(3): 195–204.
Muttiah B, Abdullah NAH, 2025, Natural Compounds in Ovarian Cancer: Mechanistic Insights and Therapeutic Potential. Front Pharmacol, 16: 1687805.
Harrath AH, Jalouli M, Al-Zharani M, et al., 2026, Recent Update Targeting Autophagy-Apoptosis Crosstalk Using Bioactive Natural Products for Ovarian Cancer Treatment. Biomedicines, 14(1): 212.
Silva-Pinto PA, de Pontes JTC, Aguilar-Moron B, et al., 2025, Phytochemical Insights into Flavonoids in Cancer: Mechanisms, Therapeutic Potential, and the Case of Quercetin. Heliyon, 11(4): e42682.
Li XR, Qi L, Zhang XW, et al., 2025, Quercetin and Nano-Derivatives: Potential and Challenges in Cancer Therapy. Int J Nanomedicine, 20: 6701–6720.
Maciejczyk A, Surowiak P, 2013, Quercetin Inhibits Proliferation and Increases Sensitivity of Ovarian Cancer Cells to Cisplatin and Paclitaxel. Ginekol Pol, 84(7): 590–595.
Wang S, Zhao Z, Yu L, et al., 2025, Identification of Quercetin as a Natural MMP1 Inhibitor for Overcoming Cisplatin Resistance in Epithelial Ovarian Cancer. J Cancer, 16(8): 2578–2594.
Shamsi M, Babaahmadi-Rezaei H, Khedri A, et al., 2025, A Novel Approach to Overcome Cisplatin Resistance in Ovarian Cancer: Revealing the Synergistic Potential of Quercetin-Loaded Solid Lipid Nanoparticles. Iran Biomed J, 29(1 & 2): 20–35.
Nabavi SF, Daglia M, Moghaddam AH, et al., 2014, Curcumin and Liver Disease: From Chemistry to Medicine. Compr Rev Food Sci Food Saf, 13(1): 62–77.
Kalinina EV, Hasan AAS, Tatarskiy VV, et al., 2022, Suppression of PI3K/Akt/mTOR Signaling Pathway and Antioxidant System and Reversal of Cancer Cells Resistance to Cisplatin under the Effect of Curcumin. Bull Exp Biol Med, 173(3): 371–375.
Ulker EB, Aktas EC, Seyhan MF, et al., 2024, Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-Resistant Ovarian Cancer Cells. Anticancer Res, 44(12): 5351–5359.
Zhang J, Liu J, Xu X, et al., 2017, Curcumin Suppresses Cisplatin Resistance Development Partly via Modulating Extracellular Vesicle-Mediated Transfer of MEG3 and miR-214 in Ovarian Cancer. Cancer Chemother Pharmacol, 79(3): 479–487.
Musial C, Kuban-Jankowska A, Gorska-Ponikowska M, 2020, Beneficial Properties of Green Tea Catechins. Int J Mol Sci, 21(5): 1744.
Ohishi T, Goto S, Monira P, et al., 2016, Anti-Inflammatory Action of Green Tea. Antiinflamm Antiallergy Agents Med Chem, 15(2): 74–90.
Ahmad RS, Butt MS, Sultan MT, et al., 2015, Preventive Role of Green Tea Catechins from Obesity and Related Disorders Especially Hypercholesterolemia and Hyperglycemia. J Transl Med, 13: 79.
Kaihatsu K, Yamabe M, Ebara Y, 2018, Antiviral Mechanism of Action of Epigallocatechin-3-O-Gallate and Its Fatty Acid Esters. Molecules, 23(10): 2475.
Ozduran G, Becer E, Vatansever HS, 2023, The Role and Mechanisms of Action of Catechins in Neurodegenerative Diseases. J Am Nutr Assoc, 42(1): 67–74.
Eshraghi R, Bahrami A, Iravanlou FT, et al., 2025, Cardioprotective and Anti-Hypertensive Effects of Epigallocatechin Gallate: Novel Insights Into Biological Evidence. J Clin Hypertens (Greenwich), 27(6): e70036.
Farhan M, 2022, Green Tea Catechins: Nature’s Way of Preventing and Treating Cancer. Int J Mol Sci, 23(18): 10713.
Xiao S, Jia H, Guo Y, et al., 2025, Chemoprophylactic Effects of Epigallocatechin Gallate in Female Reproductive Cancers - A Review. J Diet Suppl, 22(4): 487–510.
Li X, Hou Y, Han G, et al., 2024, S100A4/NF-kappaB Axis Mediates the Anticancer Effect of Epigallocatechin-3-Gallate in Platinum-Resistant Ovarian Cancer. iScience, 27(2): 108885.
Wang X, Jiang P, Wang P, et al., 2015, EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. PLoS One, 10(4): e0125402.
Chan MM, Soprano KJ, Weinstein K, et al., 2006, Epigallocatechin-3-Gallate Delivers Hydrogen Peroxide to Induce Death of Ovarian Cancer Cells and Enhances Their Cisplatin Susceptibility. J Cell Physiol, 207(2): 389–396.
Malaguarnera L, 2019, Influence of Resveratrol on the Immune Response. Nutrients, 11(5): 946.
Aggarwal BB, Bhardwaj A, Aggarwal RS, et al., 2004, Role of Resveratrol in Prevention and Therapy of Cancer: Preclinical and Clinical Studies. Anticancer Res, 24(5A): 2783–2840.
Jeong KJ, Cho KH, Panupinthu N, et al., 2013, EGFR Mediates LPA-Induced Proteolytic Enzyme Expression and Ovarian Cancer Invasion: Inhibition by Resveratrol. Mol Oncol, 7(1): 121–129.
Ferraresi A, Esposito A, Girone C, et al., 2021, Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migration and Platinum Resistance by Rescuing Hedgehog-Mediated Autophagy. Cells, 10(11): 3213.
Muhanmode Y, Wen MK, Maitinuri A, et al., 2022, Curcumin and Resveratrol Inhibit Chemoresistance in Cisplatin-Resistant Epithelial Ovarian Cancer Cells via Targeting P13K Pathway. Hum Exp Toxicol, 41: 9603271221095929.
Baribeau S, Chaudhry P, Parent S, et al., 2014, Resveratrol Inhibits Cisplatin-Induced Epithelial-to-Mesenchymal Transition in Ovarian Cancer Cell Lines. PLoS One, 9(1): e86987.
Engelke LH, Hamacher A, Proksch P, et al., 2016, Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780. J Cancer, 7(4): 353–363.
Ma X, Zhang X, Wang X, et al., 2023, The Role of Kaempferol in Gynaecological Malignancies: Progress and Perspectives. Front Pharmacol, 14: 1310416.
de Morais EF, de Oliveira LQR, Farias Morais HG, et al., 2024, The Anticancer Potential of Kaempferol: A Systematic Review Based on In Vitro Studies. Cancers (Basel), 16(3): 585.
Luo H, Daddysman MK, Rankin GO, et al., 2010, Kaempferol Enhances Cisplatin’s Effect on Ovarian Cancer Cells Through Promoting Apoptosis Caused by Down Regulation of c-Myc. Cancer Cell Int, 10: 16.
El-Kott AF, Shati AA, Al-Kahtani MA, et al., 2020, Kaempferol Induces Cell Death in A2780 Ovarian Cancer Cells and Increases Their Sensitivity to Cisplatin by Activation of Cytotoxic Endoplasmic Reticulum-Mediated Autophagy and Inhibition of Protein Kinase B. Folia Biol (Praha), 66(1): 36–46.
Song X, Tan L, Wang M, et al., 2021, Myricetin: A Review of the Most Recent Research. Biomed Pharmacother, 134: 111017.
Taheri Y, Suleria HAR, Martins N, et al., 2020, Myricetin Bioactive Effects: Moving from Preclinical Evidence to Potential Clinical Applications. BMC Complement Med Ther, 20(1): 241.
Gupta G, Siddiqui MA, Khan MM, et al., 2020, Current Pharmacological Trends on Myricetin. Drug Res (Stuttg), 70(10): 448–454.
Chen L, Fan T, Wang M, et al., 2024, Myricetin, a Natural Inhibitor of CD147, Increases Sensitivity of Cisplatin in Ovarian Cancer. Expert Opin Ther Targets, 28(1–2): 83–95.
Huang H, Chen AY, Ye X, et al., 2015, Myricetin Inhibits Proliferation of Cisplatin-Resistant Cancer Cells Through a p53-Dependent Apoptotic Pathway. Int J Oncol, 47(4): 1494–1502.
Ceci C, Lacal PM, Tentori L, et al., 2018, Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients, 10(11): 1756.
Liu H, Zeng Z, Wang S, et al., 2017, Main Components of Pomegranate, Ellagic Acid and Luteolin, Inhibit Metastasis of Ovarian Cancer by Down-Regulating MMP2 and MMP9. Cancer Biol Ther, 18(12): 990–999.
Elsaid FG, Alshehri MA, Shati AA, et al., 2020, The Anti-Tumourigenic Effect of Ellagic Acid in SKOV-3 Ovarian Cancer Cells Entails Activation of Autophagy Mediated by Inhibiting Akt and Activating AMPK. Clin Exp Pharmacol Physiol, 47(9): 1611–1621.
Mandal T, Shukla D, Pattanayak S, et al., 2024, Ellagic Acid Induces DNA Damage and Apoptosis in Cancer Stem-like Cells and Overcomes Cisplatin Resistance. ACS Omega, 9(50): 48988–49000.
Ruan H, Zhan YY, Hou J, et al., 2017, Berberine Binds RXRalpha to Suppress Beta-Catenin Signaling in Colon Cancer Cells. Oncogene, 36(50): 6906–6918.
Ortiz LM, Lombardi P, Tillhon M, et al., 2014, Berberine, an Epiphany Against Cancer. Molecules, 19(8): 12349–12367.
Duda-Madej A, Viscardi S, Szewczyk W, et al., 2024, Natural Alkaloids in Cancer Therapy: Berberine, Sanguinarine and Chelerythrine Against Colorectal and Gastric Cancer. Int J Mol Sci, 25(15): 8375.
Tamtaji Z, Sheikhsagha E, Behnam M, et al., 2025, Berberine and Lung Cancer: From Pure Form to Its Nanoformulations. Asia Pac J Clin Oncol, 21(5): 455–464.
Chen H, Ye C, Wu C, et al., 2023, Berberine Inhibits High Fat Diet-Associated Colorectal Cancer Through Modulation of the Gut Microbiota-Mediated Lysophosphatidylcholine. Int J Biol Sci, 19(7): 2097–2113.
Chakraborty S, Ghosh BN, 2025, Berberine and Its Impact on Breast Cancer: Unveiling Key Signalling Pathways. Mol Biol Rep, 52(1): 719.
Marverti G, Ligabue A, Lombardi P, et al., 2013, Modulation of the Expression of Folate Cycle Enzymes and Polyamine Metabolism by Berberine in Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cells. Int J Oncol, 43(4): 1269–1280.
Chen Q, Qin R, Fang Y, et al., 2015, Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway. Cell Physiol Biochem, 36(3): 956–965.
Mitra S, Anand U, Jha NK, et al., 2021, Anticancer Applications and Pharmacological Properties of Piperidine and Piperine: A Comprehensive Review on Molecular Mechanisms and Therapeutic Perspectives. Front Pharmacol, 12: 772418.
Wiraswati HL, Ma’ruf IF, Sharifi-Rad J, et al., 2025, Piperine: An Emerging Biofactor with Anticancer Efficacy and Therapeutic Potential. Biofactors, 51(1): e2134.
Wojtowicz K, Sterzynska K, Swierczewska M, et al., 2021, Piperine Targets Different Drug Resistance Mechanisms in Human Ovarian Cancer Cell Lines Leading to Increased Sensitivity to Cytotoxic Drugs. Int J Mol Sci, 22(8): 4243.
Achkar IW, Mraiche F, Mohammad RM, et al., 2017, Anticancer Potential of Sanguinarine for Various Human Malignancies. Future Med Chem, 9(9): 933–950.
Ullah A, Ullah N, Nawaz T, et al., 2023, Molecular Mechanisms of Sanguinarine in Cancer Prevention and Treatment. Anticancer Agents Med Chem, 23(7): 765–778.
Sarkhosh-Inanlou R, Molaparast M, Mohammadzadeh A, et al., 2020, Sanguinarine Enhances Cisplatin Sensitivity via Glutathione Depletion in Cisplatin-Resistant Ovarian Cancer (A2780) Cells. Chem Biol Drug Des, 95(2): 215–223.
Zhang W, Zhang Y, Fan J, et al., 2024, Pharmacological Activity of Capsaicin: Mechanisms and Controversies (Review). Mol Med Rep, 29(3): 38.
Brown KC, Sugrue AM, Conley KB, et al., 2024, Anti-Cancer Activity of Capsaicin and Its Analogs in Gynecological Cancers. Adv Cancer Res, 164: 241–281.
Sailo BL, Garhwal A, Mishra A, et al., 2025, Potential of Capsaicin as a Combinatorial Agent to Overcome Chemoresistance and to Improve Outcomes of Cancer Therapy. Biochem Pharmacol, 236: 116828.
Arzuman L, Beale P, Chan C, et al., 2014, Synergism from Combinations of Tris(benzimidazole) Monochloroplatinum(II) Chloride with Capsaicin, Quercetin, Curcumin and Cisplatin in Human Ovarian Cancer Cell Lines. Anticancer Res, 34(10): 5453–5464.
Li S, Xiong Q, Shen Y, et al., 2024, Toosendanin: Upgrade of an Old Agent in Cancer Treatment. Chin J Nat Med, 22(10): 887–899.
Hu M, Xu M, Chen Y, et al., 2023, Therapeutic Potential of Toosendanin: Novel Applications of an Old Ascaris Repellent as a Drug Candidate. Biomed Pharmacother, 167: 115541.
Wang G, Li L, Li Y, et al., 2023, Toosendanin Reduces Cisplatin Resistance in Ovarian Cancer through Modulating the miR-195/ERK/beta-Catenin Pathway. Phytomedicine, 109: 154571.
Liu Z, Ma L, Zhou GB, 2011, The Main Anticancer Bullets of the Chinese Medicinal Herb, Thunder God Vine. Molecules, 16(6): 5283–5297.
Song J, He GN, Dai L, 2023, A Comprehensive Review on Celastrol, Triptolide and Triptonide: Insights on Their Pharmacological Activity, Toxicity, Combination Therapy, New Dosage Form and Novel Drug Delivery Routes. Biomed Pharmacother, 162: 114705.
Wang R, Ma X, Su S, et al., 2018, Triptolide Antagonized the Cisplatin Resistance in Human Ovarian Cancer Cell Line A2780/CP70 via hsa-mir-6751. Future Med Chem, 10(16): 1947–1955.
Zhong Y, Le F, Cheng J, et al., 2026, Triptolide Inhibits JAK2/STAT3 Signaling and Induces Lethal Autophagy through ROS Generation in Cisplatin-Resistant SKOV3/DDP Ovarian Cancer Cells. Oncol Rep, 55(3): 43.
Zhong YY, Chen HP, Tan BZ, et al., 2013, Triptolide Avoids Cisplatin Resistance and Induces Apoptosis via the Reactive Oxygen Species/Nuclear Factor-kappaB Pathway in SKOV3(PT) Platinum-Resistant Human Ovarian Cancer Cells. Oncol Lett, 6(4): 1084–1092.
Seneme EF, Dos Santos DC, de Lima CA, et al., 2022, Effects of Myristicin in Association with Chemotherapies on the Reversal of the Multidrug Resistance (MDR) Mechanism in Cancer. Pharmaceuticals (Basel), 15(10): 1233.
Bao H, Muge Q, 2021, Anticancer Effect of Myristicin on Hepatic Carcinoma and Related Molecular Mechanism. Pharm Biol, 59(1): 1126–1132.
Song J, Xu X, He S, et al., 2023, Myristicin Suppresses Gastric Cancer Growth via Targeting the EGFR/ERK Signaling Pathway. Curr Mol Pharmacol, 16(7): 712–724.
Sufina Nazar S, Ayyappan JP, 2024, Mechanistic Evaluation of Myristicin on Apoptosis and Cell Cycle Regulation in Breast Cancer Cells. J Biochem Mol Toxicol, 38(6): e23740.
Seneme EF, Dos Santos DC, Silva EMR, et al., 2021, Pharmacological and Therapeutic Potential of Myristicin: A Literature Review. Molecules, 26(19): 5914.
Wu KH, Lee WJ, Cheng TC, et al., 2019, Study of the Antitumor Mechanisms of Apiole Derivatives (AP-02) from Petroselinum crispum through Induction of G0/G1 Phase Cell Cycle Arrest in Human COLO 205 Cancer Cells. BMC Complement Altern Med, 19(1): 188.
Misic D, Tadic V, Korzeniowska M, et al., 2020, Supercritical Fluid Extraction of Celery and Parsley Fruit-Chemical Composition and Antibacterial Activity. Molecules, 25(14): 3163.
Afonso de Lima C, de Souza Bueno IL, Nunes Siqueira, et al., 2020, Reversal of Ovarian Cancer Cell Lines Multidrug Resistance Phenotype by the Association of Apiole with Chemotherapies. Pharmaceuticals (Basel), 13(10): 327.
Arzuman L, Beale P, Yu JQ, et al., 2015, Monofunctional Platinum-Containing Pyridine-Based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models. Anticancer Res, 35(5): 2783–2794.
Koren Carmi Y, Mahmoud H, Khamaisi H, et al., 2020, Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion. Int J Mol Sci, 21(18): 653.
Chen H, Landen CN, Li Y, et al., 2013, Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane. J Oncol, 2013: 872957.
Yunos NM, Beale P, Yu JQ, et al., 2011, Synergism from Sequenced Combinations of Curcumin and Epigallocatechin-3-gallate with Cisplatin in the Killing of Human Ovarian Cancer Cells. Anticancer Res, 31(4): 1131–1140.
Cai YY, Lin WP, Li AP, et al., 2013, Combined Effects of Curcumin and Triptolide on an Ovarian Cancer Cell Line. Asian Pac J Cancer Prev, 14(7): 4267–4271.
Nam JS, Sharma AR, Nguyen LT, et al., 2016, Application of Bioactive Quercetin in Oncotherapy: From Nutrition to Nanomedicine. Molecules, 21(1): E108.
Trofin AM, Scripcariu DV, Filipiuc SI, et al., 2025, From Nature to Nanomedicine: Enhancing the Antitumor Efficacy of Rhein, Curcumin, and Resveratrol. Medicina (Kaunas), 61(6): 981.
Niedzwiecki A, Roomi MW, Kalinovsky T, et al., 2016, Anticancer Efficacy of Polyphenols and Their Combinations. Nutrients, 8(9): 552.
Cui Y, Zhou Q, Jin M, et al., 2024, Research Progress on Pharmacological Effects and Bioavailability of Berberine. Naunyn Schmiedebergs Arch Pharmacol, 397(11): 8485–8514.
Quijia CR, Araujo VH, Chorilli M, 2021, Piperine: Chemical, Biological and Nanotechnological Applications. Acta Pharm, 71(2): 185–213.
Atriya A, Majee C, Mazumder R, et al., 2023, Insight into the Various Approaches for the Enhancement of Bioavailability and Pharmacological Potency of Terpenoids: A Review. Curr Pharm Biotechnol, 24(10): 1228–1244.
Le Roy J, Huss B, Creach A, et al., 2016, Glycosylation Is a Major Regulator of Phenylpropanoid Availability and Biological Activity in Plants. Front Plant Sci, 7: 735.
Zeinali R, Zaeifi D, Zolfaghari-Moghaddam, et al., 2025, Current Advances in Nanocarriers for Cancer Therapy. Int J Nanomedicine, 20: 12217–12262.
Din FU, Aman W, Ullah I, et al., 2017, Effective Use of Nanocarriers as Drug Delivery Systems for the Treatment of Selected Tumors. Int J Nanomedicine, 12: 7291–7309.
Asiri A, Bokahri BT, Sadaf, et al., 2025, Curcumin, EGCG and Apigenin in Cervical Cancer: Mechanistic Insights and Therapeutic Potential. Front Pharmacol, 16: 1592395.
Khan MM, Madni A, Tahir N, et al., 2020, Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles. Int J Nanomedicine, 15: 2207–2217.
Koochaki R, Amini E, Zarehossini S, et al., 2024, Alkaloids in Cancer Therapy: Targeting the Tumor Microenvironment and Metastasis Signaling Pathways. Fitoterapia, 179: 106222.
Islam MR, Rahman MM, Dhar PS, et al., 2023, The Role of Natural and Semi-Synthetic Compounds in Ovarian Cancer: Updates on Mechanisms of Action, Current Trends and Perspectives. Molecules, 28(5): 2070.
Shi M, Zhang MJ, Yu Y, et al., 2023, Curcumin Derivative NL01 Induces Ferroptosis in Ovarian Cancer Cells via HCAR1/MCT1 Signaling. Cell Signal, 109: 110791.